It also signals the brain to reduce appetite and food cravings
Semaglutide (Wegovy and Ozempic) is an FDA-approved GLP-1 agonist that is used to treat obesity, type 2 diabetes, and weight-related health conditions such as metabolic dysfunction-associated steatohepatitis (MASH)
[29] examined treatment resistance in IIH (defined by authors as composite of indicators including requirement for escalation of medical therapy, progression to surgical intervention, need for CSF diversion procedures, or optic nerve decompression or sheath fenestration)) and noted a trend toward fewer refractory cases with tirzepatide (20.5% risk reduction, RR 0.795, p = 0.019 at 24 months)
Compounded versions lack standardization
Designed to reduce appetite, decrease energy intake, and increase satiety, CagriSema has shown promising results in both weight management and type 2 diabetes